Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor
- PMID: 15589042
- DOI: 10.1016/j.jneuroim.2004.08.018
Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor
Abstract
The proliferation of human lymphoblastoma cell line (H9) was differently stimulated by Peptide Histidine Methionine (PHM) and Vasoactive Intestinal Peptide (VIP). PHM induced a cyclic AMP (cAMP) accumulation, abolished by Adenylate Cyclase (AC) inhibitors leading to a loss of proliferative effect. VIP mitogenic activity was Pertussis toxin (PTX) sensitive and AC inhibitors insensitive. Pharmacological experiments performed on H9 membranes with or without a GTP analogue indicated expression of both GTP-insensitive and -sensitive PHM/VIP high-affinity binding sites (HA). H9 cells expressed only the VPAC1 receptor. VIP(10-28), known as a VPAC1 antagonist, bond to all GTP-insensitive PHM sites and inhibited evenly the PHM and VIP mitogenic actions. These data strongly suggested different mechanisms initiated by VIP and PHM and highlighted the key role of GTP-insensitive binding sites in the control of cell proliferation.
Similar articles
-
The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.Neuropeptides. 2001 Apr;35(2):117-26. doi: 10.1054/npep.2001.0853. Neuropeptides. 2001. PMID: 11384207
-
Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.Gen Comp Endocrinol. 2004 Jun;137(2):187-95. doi: 10.1016/j.ygcen.2004.03.007. Gen Comp Endocrinol. 2004. PMID: 15158130
-
The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells.J Neuroimmunol. 2004 Apr;149(1-2):167-81. doi: 10.1016/j.jneuroim.2003.12.008. J Neuroimmunol. 2004. PMID: 15020077
-
Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update.Peptides. 2007 Sep;28(9):1655-66. doi: 10.1016/j.peptides.2007.04.006. Epub 2007 Apr 19. Peptides. 2007. PMID: 17555844 Review.
-
[Peptide histidine-isoleucine and and its human analogue peptide histidine-methionine: localization, receptors and biological function].Postepy Hig Med Dosw (Online). 2004 Feb 26;58:18-26. Postepy Hig Med Dosw (Online). 2004. PMID: 15069375 Review. Polish.
Cited by
-
Vasoactive intestinal peptide signaling axis in human leukemia.World J Biol Chem. 2011 Jun 26;2(6):146-60. doi: 10.4331/wjbc.v2.i6.146. World J Biol Chem. 2011. PMID: 21765981 Free PMC article.
-
Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells.Med Oncol. 2019 Sep 27;36(11):91. doi: 10.1007/s12032-019-1312-y. Med Oncol. 2019. PMID: 31560089
-
Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.J Mol Neurosci. 2008 Nov;36(1-3):286-91. doi: 10.1007/s12031-008-9071-9. Epub 2008 May 20. J Mol Neurosci. 2008. PMID: 18491045
-
Vasoactive intestinal peptide induces proliferation of human hepatocytes.Cell Prolif. 2018 Oct;51(5):e12482. doi: 10.1111/cpr.12482. Epub 2018 Jul 20. Cell Prolif. 2018. PMID: 30028555 Free PMC article.
-
Antiproliferative effects of PACAP and VIP in serum-starved glioma cells.J Mol Neurosci. 2013 Oct;51(2):503-13. doi: 10.1007/s12031-013-0076-7. Epub 2013 Jul 31. J Mol Neurosci. 2013. PMID: 23900722
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources